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Monitoring malignant progression and disease recurrence post-
therapy are central challenges to improving the outcomes of
patients with multiple myeloma (MM). Whereas current detection
methods that rely upon bone marrow examination allow for
precise monitoring of minimal residual disease and can help to elu-
cidate clonal evolution, they do not take into account the spatial
heterogeneity of the tumor microenvironment. As such, they are
uninformative as to the localization of malignant plasma cells and
may lead to false negative results. With respect to the latter chal-
lenge, clinically-available imaging agents are neither suﬃciently
sensitive nor speciﬁc enough to detect minute plasma cell popu-
lations. Here, we sought to explore methods by which to improve
detection of MM cells within their natural bone marrow environ-
ment, using whole-animal magnetic resonance imaging to
longitudinally monitor early-stage disease as well as to enhance
tumor detection after systemic therapy. We conducted a proof-of-
concept study to demonstrate that ultra-small (<5 nm) gadoli-
nium-containing nanoparticles bound to full-length antibodies
against the B-cell maturation antigen (BCMA) exhibit rapid tumor
uptake followed by renal clearance, improving the signal-to-noise
ratio for MM detection beyond levels that are currently aﬀorded by
other FDA-approved clinical imaging modalities. We anticipate that
when combined with bone marrow or blood biopsy, such imaging
constructs could help to augment the eﬀective management of
patients with MM.
Introduction
Currently-available diagnostic methods to detect the malignant
plasma cells of multiple myeloma (MM) and to follow either
their therapeutic responses or proliferation rely upon frequent
serologic studies and serial bone marrow examinations. Imaging
modalities help in the further evaluation of systemic disease
burden; they are employed to localize malignant plasma cells
that are missed during bone marrow aspiration and biopsy,
which are otherwise used to detect minimal residual disease and
which are performed in only one foci of bony pelvis.1 Despite
eﬀorts to combine modalities, the ability to detect MM at its ear-
liest stages (e.g., smoldering myeloma) or post-remission is still
very limited.2 Establishment of novel imaging methods could
have a transformative impact on the care of MM patients and
those with other hematologic malignancies, enabling noninva-
sive and repetitive testing to visualize malignant cells at earlier
time points and when present even in focal distribution patterns
that would otherwise preclude identification.
Techniques for magnetic resonance imaging (MRI) with
conventional FDA-approved agents are being developed and
have shown to be more reliable for assessing disease burden,3
for enabling accurate disease prognostication,4 as well as for
following therapeutic responses in MM patients when com-
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pared to computed tomography (CT), single-photon emission
computed tomography (SPECT), or 18-fluorodeoxyglucose
(18F-FDG)-based positron emission tomography (PET).5 While
MRI can better distinguish between benign and malignant
lesions and can detect bone marrow infiltration at earlier time
points,6 current protocols are time-consuming, expensive, and
rely on the passive accumulation of non-targeted contrast
agents within the tumor microenvironment,7 which has,
hitherto, limited both their detection specificity and sensi-
tivity. Changes seen by conventional MRI are slow to normalize
after treatment; and, current techniques are unable to dis-
tinguish between remodeling bone and residual disease.6,8,9
While SPECT and 18F-FDG PET are able to accurately identify
plasma cell populations,1 they utilize ionizing radiation that
prevents repetitive testing in short intervals. 18F-FDG PET also
displays poor detection sensitivity for malignant plasma cells
in the residual disease state, which are more slowly
proliferative.10,11
To improve upon current imaging modalities, we explored
the development of an MM-targeted contrast agent that uti-
lizes short MRI sequences to identify minute tumor cell popu-
lations with high spatial localization. Gadolinium (Gd)-con-
taining nanoparticles, including ones conjugated to anti-
bodies, have previously been utilized for imaging of solid
tumors.12 These constructs, which have ranged in size from
10–400 nm in diameter,13,14 have generally demonstrated
modest contrast enhancement in subcutaneously-implanted
tumor models, a preponderance for liver accumulation, and
minimal renal clearance,15 raising concerns for potentially
longer-term side eﬀects related to Gd exposure. We have pre-
viously demonstrated that ultra-small (<5 nm) Gd-containing
nanoparticles enhance tumor uptake, improve contrast
imaging, and exhibit complete renal clearance in small animal
models16 and in nonhuman primates.17 To facilitate clinical
translation, we have further modified a process for their batch
manufacturing that is being employed in an ongoing phase I
trial (NCT02820454, NCT03308604), assessing their biodistri-
bution and safety.
In the present work, whole-animal imaging of ultra-small
(<5 nm) Gd-containing nanoparticles conjugated to mono-
clonal antibodies was pursued in order to enable rapid detec-
tion of clonal plasma cells in the bone marrow environment.
While the use of antibodies has long been proposed for the
targeting of nanoparticle-based contrast agents by binding
receptors that are overexpressed on tumor cell surfaces,18,19
the sizes of these constructs (30–200 nm in diameter)20 have
been much larger than those of full monoclonal antibodies or
of their molecular-conjugates (10–15 nm × 3–5 nm in dimen-
sion).21 As such, to date their pharmacology has been largely
dictated by the nanoparticle rather than by the antibody.
Moreover, conventional nanoparticle-antibody constructs have
demonstrated circulation times on the order of hours, have
achieved minimal tumor-uptake via passive modes of target-
ing, and have been shown to be largely distributed to organs
of the reticuloendothelial system due to uptake by resident
macrophages that clear them from the circulation.22 Most pre-
clinical studies with such agents have further been conducted
in subcutaneous xenograft models23,24 that do not recapitulate
the vascular patterns found in the natural tumor
environment;25,26 not surprisingly, many of these constructs
have exhibited no diﬀerences when compared to their untar-
geted counterparts with respect to their in situ relaxivity
values, their required systemic doses, and/or their ability to
achieve tumor localization,13 which has stymied their further
clinical development. To circumvent these challenges and to
develop antibody-targeted nanoparticles that exhibit high sen-
sitivity and specificity for malignant plasma cells, we fabri-
cated ultra-small, sub-5 nm nanoparticles (NPs) that were con-
jugated to antibodies against the signaling lymphocytic acti-
vation molecule-F7 (SLAMF7) or the B-cell maturation antigen
(BCMA). Both antigens are highly expressed and almost exclu-
sively present on the surfaces of B-cells;27,28 and, BCMA plays
an important role in plasma cell transformation and MM
progression29,30 (Fig. 1A), making it an attractive and specific
biomarker for MM detection.
To generate our MM-targeted contrast agents, Gd-contain-
ing NPs that possessed free amino groups on their surfaces
were conjugated to anti-SLAMF7 or anti-BCMA antibodies,
using a bissulfosuccinimidyl suberate crosslinker (Fig. 1B). We
subsequently evaluated the targeting eﬃciencies of the resul-
tant ultra-small nanoparticle-antibody complexes both in vitro
and in vivo prior to performing a comparative study to deter-
mine their detection capabilities. We demonstrate that these
constructs are able to eﬀectively target malignant plasma cells,
to improve longitudinal detection of disease burden, and to
more accurately determine early therapeutic responses when
compared to CT, 18F-FDG PET/CT, and the serologic free light-
chain assay in an orthotopic murine xenograft model of MM
that recapitulates its genetic and histologic features.
Results
Development of antibody-conjugated ultra-small Gd-
containing nanoparticles
The rational selection of SLAMF7 and BCMA as targets for
molecular imaging in MM was based on the results of the
Achilles dataset.31 Z-Score standardized expression values of
various genes were tested for diﬀerential expression between
normal and several disease states (i.e., monoclonal gammopa-
thy of undetermined significance (MGUS), smoldering, new,
and relapsed MM), using DESeq2 to calculate log-fold changes
in expression and corresponding p-values, which were adjusted
for multiple hypothesis testing; note that log-fold changes
were considered significant when adjusted p-values were less
than 0.05 (i.e., −log 10(p) < 1.3) (Fig. 1A). Chemical coupling of
mouse anti-human SLAMF7 and BCMA antibodies to NPs,
using EDC/NHS chemistry, led to the generation of their
respective antibody-conjugated nanoparticle constructs, which
are denoted as NP-SLAMF7 and NP-BCMA, respectively; their
structures were validated by high-performance liquid chrom-
atography, by polysaccharide analysis using carbohydrate gel
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electrophoresis, and by matrix-assisted laser desorption/ioniza-
tion mass spectrometry (ESI Fig. 1A–C†). Dynamic light scatter-
ing (DLS) measurements confirmed that the average hydrodyn-
amic diameters of both NP-SLAMF7 (12.9 ± 2.3 nm by inten-
sity-weighted DLS; 8.11 ± 0.83 nm by number-weighted DLS)
and NP-BCMA (10.01 ± 2.03 nm by intensity-weighted DLS;
7.85 ± 0.85 nm by number-weighted DLS) were larger than that
of the unmodified NP (4.4 ± 1.4 nm by intensity-weighted DLS;
2.93 ± 1.14 nm by number-weighted DLS; Fig. 1C). NP-antibody
complexes remained stable over time and even under acidic
suspension conditions (ESI Fig. 1C and D†). The relaxivity
values remained constant before and after NP conjugation to
diﬀerent antibodies (r1 = 5.90, 5.49, 5.33 mM
−1 s−1 for NP,
NP-BCMA, and NP-SLAMF7, respectively); and, these values
were similar to those of the clinically-available agent
Mangevist™ (r1 = 4.73 mM
−1 s−1, Fig. 1D).
The enhanced in vitro targeting eﬃciency of NP-BCMA was
subsequently verified by employing human MM cell lines
(MM·1S and KMS11) and by using a competitive binding
assay,32 wherein cells were incubated with a combination con-
sisting of purified human IgG, an anti-BCMA antibody, unmo-
dified NPs, or NP-BCMA along with PerCP/Cy5.5-conjugated
anti-BCMA antibodies at 3 diﬀerent molar ratios. The results
obtained with NP-BCMA were similar to those seen with the
anti-BCMA antibody alone (Fig. 1E), confirming that antibody
specificity was maintained after NP conjugation. Flow cytometry
analyses demonstrated that 74.1 ± 2.9% of MM.1S cells were
labeled with NP-BCMA complexes by 30 min post-incubation; in
contrast, unmodified NPs labeled only 20 ± 4.9% of the cellular
populations under identical conditions (p-value <0.001). The
exact concentrations of Gd in the final cellular suspensions
were determined by inductively-coupled plasma mass spec-
trometry (ICP-MS), which verified a nearly two-fold increase in
labeling of both MM cells lines (MM·1S and KMS11) by using
NP-BCMA as compared to unmodified NPs (Fig. 1F). Cellular
viability assays on the same cultured cell lines demonstrated
that neither the unmodified NPs, the free anti-SLAMF7 or anti-
BCMA antibodies, nor the nanoparticle-antibody complexes
Fig. 1 Rational design of a targeted contrast agent for multiple myeloma. (A) Volcano plot comparing the expression levels of SLAMF7 and BCMA as
a function of disease stage for patients with plasma cell dyscrasias identiﬁed from the Achilles dataset.31 MGUS: Monoclonal gammopathy of unde-
termined signiﬁcance; SMM: smoldering multiple myeloma. (B) Schematic representation of the conjugation of Gd-bound, DOTA-functionalized
(red), and silica-based nanoparticles (NPs; blue) to monoclonal antibodies (grey) targeting malignant plasma cells (yellow), using a homobifunctional
linker (green). (C) Hydrodynamic sizes of the NP-antibody complexes of anti-SLAMF7 (NP-SLAMF7) and anti-BCMA antibodies (NP-BCMA) and (D)
their corresponding relaxivity (r1) values. (E) Competitive labeling assay32 in which KMS11 and MM.1S cells were ﬁrst incubated with a combination
consisting of either NP-BCMA, anti-BCMA, or an IgG antibody along with a PerCP/Cy5.5-conjugated anti-BCMA antibody at diﬀerent molar ratios
and then subjected to ﬂow cytometry. The lower signal observed at 1 : 1 ratio of unlabeled anti-BCMA antibody or NP-BCMA to PerCP/Cy5.5-conju-
gated anti-BCMA antibody conﬁrms that the NP conjugate competes with the ﬂuorophore-conjugated antibody for cellular labeling and
does not aﬀect the antibody’s binding ability. (F) Uptake of various Gd-containing NPs as assessed by ICP-MS at 30 min after cellular incubation.
* p-Value <0.05, Mann Whitney test.
Nanoscale Communication
This journal is © The Royal Society of Chemistry 2019 Nanoscale
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
28
/2
01
9 
11
:0
8:
58
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
imparted any in vitro toxicities at protein (10 000 µg mL−1) and
NP concentrations (1 µg mL−1) that were 125× and 4× higher,
respectively, than those that would be expected in the blood
stream after intravenous (IV) administration (ESI Fig. 2†).
In vivo targeting of plasma cells using nanoparticle-antibody
complexes
We next evaluated the targeting eﬃciency of NP-SLAMF7 and
NP-BCMA to detect plasma cells in a murine model of MM
that was established via intravenous (IV) dissemination of luci-
ferase (LUC) and green fluoresence protein (GFP)-expressing
MM·1S cells (LUC+-MM·1SGFP) followed by their bone marrow
engraftment within immunocompromised SCID-beige mice.
Tumor burden was followed by bioluminescence imaging (BLI)
at bi-weekly intervals, starting on day 19 after tumor xenotrans-
plantation (ESI Fig. 3†). An MRI study was undertaken to
compare (at an equivalent systemic level of ∼175 μmol Gd per
kg; see Materials and methods and ESI Fig. 4†) the eﬃciencies
of the various nanoparticle constructs (NP, NP-IgG,
NP-SLAMF7, or NP-BCMA) to identify identical plasma cell
burdens; the results were further evaluated against those that
could be achieved with a clinically-available MRI contrast
agent (i.e., Magnevist™), which was administered at a stan-
dard dose (200 μmol Gd per kg). Note that Magnevist™ is a
molecular probe made of gadopentate dimeglumine chelates;
it exhibits a nanometric size, a short circulation time (half-life
<10 min), and complete renal clearance that underlie its estab-
lished safety profile. As such, Magnevist is routinely used in
the clinic as a preferred MRI contrast agent.
To compare our experimental constructs to Magnevist™,
Gd uptake was visualized in the spines (Fig. 2A and ESI
Fig. 5†) and femurs of treated animals (ESI Fig. 6A†), using a
7T Bruker Biospin MRI scanner and by employing a T1-gradi-
ant echo (GRE) sequence at 5 and 30 min after systemic injec-
tion as well as various T2 sequences with and without fat sup-
pression. The specificity of each of the administered contrast
agents to target MM cells was confirmed by animal sacrifice
immediately after MRI; the vertebral tissues of each animal
were harvested for histologic assessment after staining with
H&E (ESI Fig. 7†); and, fluorescence microscopy of parallel sec-
tions was conducted in order to determine the spatial localiz-
ation of various NP formulations (by the near-infrared fluo-
Fig. 2 Selection of the optimal antibody-conjugated nanoparticle for malignant plasma-cell targeting. (A) MRI of tumor deposits comprised of
LUC+-MM·1SGFP cells (yellow arrows) in mice on day 19 after tumor cell implantation and after the administration of various contrast formulations (n
= 5 mice per group). (B) Representative ﬂuorescence micrographs of bone marrow taken from the spines of the same mice treated with each of the
diﬀerent NP formulations, conﬁrming that uptake of NPs in the tumor microenvironment is driven by speciﬁc binding of their associated anti-
SLAMF7 and anti-BCMA antibodies to receptors on cellular surfaces. Plasma-cells are visualized via the ﬂuorescence of their intrinsic GFP reporter
(green) and the NP formulations by the emission of Cy5.5 bound to their surfaces (red). Scale bar = 100 µm. (C) Signal-to-noise ratio (SNR) of the
spine over time normalized to that of the baseline acquisition; note that NP, NP-IgG, NP-SLAMF7 and NP-BCMA were administered at an equivalent
dose level based on Gd (∼175 μmol kg−1) while Magnevist™ was injected at a standard dose (200 μmol Gd per kg). A two-tailed t-test with Welch’s
correction was performed to compare groups. * p < 0.05, ** p < 0.005, and *** p < 0.001.
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rescence of Cy5.5, which was used for their labeling at the
time of preparation) with respect to MM·1S cells (which were
visualized via their intrinsic GFP emission) (Fig. 2B).
For quantitative comparisons of MRI sensitivity, the in vivo
signal-to-noise ratio (SNR) for the detection of plasma cell
populations was enumerated in each image taken at diﬀerent
time points after the administration of the various Gd-contain-
ing contrast agents; signal intensities were quantified after a
3D segmentation of the spines (Fig. 2C) and femurs of each
animal (ESI Fig. 6†). This quantification demonstrated the
enhanced sensitivity of NP-SLAMF7 and NP-BCMA, when com-
pared to the passive targeting agents (NP, NP-IgG, and
Magnevist™), to detect plasma cell populations. As soon as
30 min after IV injection, animals that had been administered
NP-SLAMF7 demonstrated a 1.76-fold increase in the SNR for
plasmacytomas in the spine while those that had received
NP-BCMA exhibited a 2.98-fold enhancement. The decrease in
MRI contrast observed from 30 min to 3 h after systemic
administration could be attributable to bioprocessing of the
nanoparticle-antibody complexes (ESI Fig. 8†), which would be
expected to result in their breakdown with subsequent loss of
T1 signal as has been demonstrated with other constructs.33
ICP-MS was used to measure the Gd levels in excised
organs taken from MM·1S tumor-bearing mice that were sacri-
ficed at various time points after the administration of untar-
geted NP; the results confirmed that 4.11 ± 3.44 μmol Gd per
kg, which equates to 0.11 ± 0.9% of the injected dose of Gd
per gram (%ID g−1), localized to the spine at 30 min post-injec-
tion (Fig. 3A and ESI Fig. 9†). The corresponding values from
the spines of mice sacrificed at 30 min after the administration
of NP-SLAMF7 (65.82 ± 23.29 μmol Gd per kg; 1.89 ± 0.67%ID
g−1) or NP-BCMA were significantly greater (153.54 ±
25.40 μmol Gd per kg; 4.4 ± 0.7%ID g−1). Together, these find-
ings support rapid washout of unbound contrast reagent and
Fig. 3 Biodistribution, pharmacokinetic and toxicity evaluation of gadolinium-containing nanoparticles and their antibody complexes. (A) Tissue
distribution of unconjugated (NP), anti-SLAMF7 antibody-conjugated (NP-SLAMF7), and anti-BCMA antibody-conjugated (NP-BCMA) Gd-containing
nanoparticles in MM·1S tumor-bearing mice on day 19 after tumor cell implantation; quantiﬁcation of the percentages of the injected dose of Gd
per gram tissue (%ID g−1) in various organs was performed by ICM-MS (n = 5 mice per time point). Li: Liver, Sp: spine, F: femur, Lu: lung, H: heart, S:
spleen, Ki: kidneys, B: bladder. (B) Pharmacokinetic study demonstrating changes in the Gd-concentrations in blood from healthy balb/c mice that
had been administered NP, NP-IgG, NP-SLAMF7, or NP-BCMA as determined by ICM-MS measurements, which were performed on serial blood
samples drawn from the same animals (n = 5 mice per time point). Statistical analyses were performed by using a two-tailed t-test with Welch’s cor-
rection to compare the NP group to others. No signiﬁcant diﬀerences were observed between the antibody-conjugated NP groups (one-way
ANOVA). (C) Changes in the body weights of healthy balb/c mice as a function of time after administration of a single dose of various Gd-containing
contrast agents (n = 5 mice per group for Magnevist, NP, and NP-SLAMF7; n = 8 mice per group for NP-BCMA). No signiﬁcant diﬀerences were
observed between mice in the NP-BCMA and NP groups (repeated measurements ANOVA test). (D) H&E stained micrographs of tissue sections from
healthy balb/c mice sacriﬁced at various time points after the administration of a single dose of NP-BCMA.
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the ability of the antibody-targeted NPs to bind resident
plasma cells. With an average disease burden comprising
6.79 ± 0.58% of the spinal volume (as determined by MRI; ESI
Fig. 10†), NP-BCMA is, therefore, able to achieve a localized
tumor concentration of Gd that is significantly higher than
that found throughout the spinal volume at an equivalent dose
of untargeted NP, which is otherwise a vascular pooling agent.
NP-BCMA further demonstrates better tumor uptake than
NP-SLAMF7 (p = 0.0045, one-sided paired t-test), which may be
attributed to the greater numbers of surface BCMA antigens
per MM·1S cell. The observed SNRs for plasmacytomas visual-
ized by MRI (Fig. 2C and ESI Fig. 5†) correlate well with simu-
lations of the expected SNRs (ESI Fig. 11†), demonstrating that
nanoparticle-antibody complexes are able to achieve Gd con-
centrations that are >100 µM throughout the measured tumor
volume. While we have previously observed eﬀective contrast
of subcutaneous tumors after the administration of untargeted
NP (via 7T MRI),34,35 NP-BCMA specifically binds plasmacyto-
mas and enables visualization of minute tumor populations in
their natural environment. Note that only trace amounts of Gd
were otherwise observed in the liver, kidney, lungs, or in any
other organ at 72 h after the administration of each of the
agents (i.e., NP, NP-SLAMF7, or NP-BCMA; Fig. 3A), supporting
their systemic elimination. The pharmacokinetic profiles of
NP-SLAMF7 and NP-BCMA were similar (Fig. 3B); and, their cir-
culatory half-lives were longer than that of the unmodified NP
(t1/2 = 16.1, 22.3, 25.2 and 30.3 min for NP, NP-IgG, NP-SLAMF7,
and NP-BCMA, respectively). These enhancements in vascular
persistence may be attributed to their slightly larger sizes and
to the intrinsic properties of the selected antibodies.
Surprisingly, NP-SLAMF7 and NP-BCMA were found to
exhibit rapid renal clearance, which could be expected to limit
their long-term exposure to healthy organs. Urine was col-
lected at various time points and assayed for its Gd content by
ICP-MS, demonstrating that >95% and >93% of the injected
dose was found in the urine at 72 h after administration of NP
and NP-BCMA, respectively (ESI Fig. 12A†). While the com-
plete renal clearance of the untargeted NP (<5 nm) has been
previously demonstrated17,36 and is consistent with the known
glomerular filtration threshold (∼6 nm),37 similar clearance of
NP-BCMA was unexpected due to the relatively larger size of
this bioconjugate (average diameter of ∼8 to 10 nm by
number vs. intensity-weighted DLS, respectively). While in vivo
decoupling of surface-bound antibody from NP-BCMA could
potentially explain these observations, which would also be con-
sistent with the loss of in vivo MRI contrast observed after
30 min (vide supra), dynamic light scattering measurements of
both normalized number- and intensity-weighted size distri-
butions confirmed that NP and NP-BCMA remained relatively
stable from administration to systemic clearance (ESI
Fig. 12B†). The exact mechanisms whereby NP-BCMA is filtered
through the kidneys, thus, remain unknown and warrant
further investigation.
Both the untargeted and antibody-conjugated NP con-
structs were tolerated by balb/c mice as evidenced by stable
animal weights and the paucity of gross adverse phenomena
(i.e., changes in general appearance, in skin and fur, in nose,
mouse and head respirations, in urine, in feces and in loco-
motor factors) over a two-week period after a single-dose IV
administration (Fig. 3C). Terminal blood studies confirmed
normal basic metabolic panels (BMPs; ESI Fig. 13A†), com-
plete blood counts (CBCs; ESI Fig. 13B†), and white blood cell
diﬀerential counts at the end of this period (ESI Fig. 13C†).
Pathology review of H&E stained tissue sections uncovered no
evidence of microarchitectural distortion (Fig. 3D). As such,
the NP-antibody complexes were deemed to exhibit no disqua-
lifying short-term toxicities that could compromise the find-
ings of their enhanced imaging performance or that could pre-
clude their continued preclinical development.
Comparisions of in vivo imaging sensitivity and specificity
Having validated the analytical capabilities of our novel con-
structs, we subsequently sought to compare MRI of NP-BCMA
with respect to each of the clinical imaging modalities that are
routinely used for the longitudinal detection of plasma cells.
We again employed a murine model of MM, consisting of the
intravascular dissemination of LUC+-MM·1SGFP cells in mice;
therapeutic debulking was subsequently conducted at 21 days
after xenotransplatation, using three doses of bortezomib
(0.5 mg kg−1) and one dose of melphalan (5.5 mg kg−1).
Tumor growth was monitored by weekly BLI as the gold stan-
dard for preclinical detection (Fig. 4A) as well as by whole-
body CT (Fig. 4B), 18F-FDG PET/CT (Fig. 4C), and by MRI of
BCMA-NP (Fig. 4D). This post-treatment model was validated
by obtaining a negative BLI signal at day 25, which corre-
sponded to the completion of bortezomib and melphalan
administration. Changes in the signal intensities (BLI), SNRs
(CT and MRI), and standard uptake values (SUVs; 18F-FDG
PET/CT) of the spine over time were subsequently used to
track disease re-expansion (Fig. 4E). In addition, the levels of
serum λ light-chains were measured at the same time points
(Fig. 4F) and served as an independent biomarker of disease
activity. Note that MM·1S cells only express the λ light-chain;
they do not express the kappa light-chain nor exhibit a spike in
their levels of M-protein.38
Results obtained by BLI, MRI, CT, 18F-FDG PET/CT, and by
the serum λ light-chain assay were compared at 1 week after
therapeutic debulking (i.e., 5 weeks after initial tumor cell
implantation). A receiver operator characteristic (ROC) curve
was generated to assess the sensitivity and specificity of each
of the 5 detection modalities to identify disease recurrence
and confirmed the superiority of MRI using NP-BCMA.
Comparisons of area-under-the-curve (AUC) for the SNR
observed with each modality and over the entire duration of
the experiment (i.e., from initial tumor cell implantation to
therapeutic debulking to eventual animal demise from tumor
regrowth) further supported these findings (Fig. 4G, ESI
Fig. 14†). To determine the analytical sensitivity of MRI of
NP-BCMA, additional mice were sacrificed on day 25 (i.e.,
immediately after tumor debulking) as well as on days 28 and
30 post tumor cell implantation, which corresponded to the
time points after which plasma cells were first visible (in the
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spine) by MRI. Flow cytometry experiments on the entire cellu-
lar populations recovered from each animal were conducted
(Fig. 4H); the results were enumerated to confirm that MRI
with NP-BCMA had a detection threshold of 2200 ± 450
plasma cells (in the spine) per mouse. As expected, the percen-
tages of plasma cells amongst the total cellular populations
(Fig. 4I), as well as the percentages of NP-BCMA-bound plasma
cells (Fig. 4J), increased as a function of time and were due to
tumor regrowth.
Conclusions
We demonstrate a proof-of-concept method in which changes
in the SNR obtained by serial MRI of an antibody-conjugated
nanoparticle-based contrast agent may be used to follow MM
activity throughout the whole-body, using highly-sensitive,
specific, and non-invasive imaging measurements made at
serial time points. Central to the success of these eﬀorts was
the utilization of ultra-small (<5 nm) nanoparticles bound to
Fig. 4 MRI of NP-BCMA as a novel biomarker for longitudinal tracking of MM activity. LUC+-MM·1SGFP tumor-bearing mice were imaged weekly by
(A) bioluminescence imaging (BLI), (B) CT, (C) 18F-FDG PET/CT, or (D) MRI at 30 min after injection of NP-BCMA to visualize tumor burden (yellow
arrows). On day 21 after tumor cell implantation, treatment with bortezomib (0.5 mg kg−1 ×3) and melphalan (5.5 mg kg−1 ×1) ensued. Thereafter,
longitudinal imaging was conducted at weekly intervals to follow disease burden. Changes in (E) BLI signal intensities, the signal-to-noise ratio (SNR)
for CT and MRI, and the standard uptake value (SUV) for 18F-FDG PET/CT were quantiﬁed to determine the sensitivity of each modality to detect
tumor cells at various time points. The red arrows correspond to the ﬁrst time points after systemic treatment. (F) Lambda light-chain levels were
similarly quantiﬁed by immunoassay. Shadowing demarcates the 90% conﬁdence interval; note that all scans and light chain assays were performed
on the same animals (n = 5 mice). (G) Receiver operator characteristic (ROC) curve at week 5, comparing the sensitivity and speciﬁcity of the 4 mod-
alities to detect the presence of residual disease. From there, a comparison of the area under the curve (AUC) over the course of treatment for the 4
detection modalities was calculated. (H) Flow cytometry histograms depicting the percentages of total plasma cells (GFP signal) and NP-BCMA-
bound plasma cells (Cy5.5 signal) at each time point. (I) The total percentages of plasma cells and (J) the percentages of NP-BCMA-bound plasma
cells in the bone marrow were enumerated and compared (n = 3 mice per group). * p-value < 0.05, Mann Whitney test.
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tumor-specific antibodies to enhance imaging contrast. Our
constructs were able to circumvent the challenges seen with
the first generation of antibody-bound nanoparticles that were
much larger in size (30–200 nm) and that have been shown to
accumulate in subcutaneous tumor models over the course of
several hours.15,39 In comparison, our agents demonstrate
maximal contrast enhancement as quickly as 30 min after
injection, which could enable their utilization within the exist-
ing clinical work-flow.
We further demonstrate that antibody-targeting of ultra-
small Gd-containing NPs enables precise localization of malig-
nant plasma cells in their natural microenvironment by MRI,
which is due to the ability of these constructs to bind tumor
cell populations and to dramatically enhance localized concen-
trations of Gd. Although similar systemic doses of Gd have
been employed for imaging with other targeted contrast
agents (via 7T MRI),13,14,40,41 many exhibited poor systemic
clearance, thereby raising safety concerns. Moreover, while Gd-
containing constructs are not suitable for use in the context of
compromised kidney function, given the well-established risks
of all Gd-containing contrast agents,42 targeted nanoparticle
constructs comprised of nonmetallic materials43 may find
utility in prompting early therapeutic discontinuation and/or
re-initiation after prolonged periods of MM remission. With
the increasing utilization of antibody-based therapies in MM
(e.g., elotuzumab,27 BCMA-targeted chimeric antigen receptor
T-cells (CAR-T),44 and daratumumab45), future formulations of
SLAMF7, BCMA and CD38-based antibody-nanoparticle com-
plexes may enable imaging to guide patient-specific thera-
peutic selection.
While our results with T1-weight MRI are promising,
further investigations will be necessary in order to ascertain
the safety of antibody-targeted ultra-small NPs as well as the
benefits that may be expected when translating our findings
from small animals to novel clinical imaging agents. As there
is a known size limit for glomerular filtration, antibody decou-
pling and/or nanoparticle degradation could account for the
phenomena of rapid renal clearance that was observed in our
current study. DLS measurements, however, did not show
appreciable changes in particle size upon renal filtration; sero-
logical and histologic studies of the kidney also did not yield
evidence of acute compromise nor eﬀacement of glomeruli. As
such, a central focus of future investigations will be the verifi-
cation and exploration of the mechanisms by which NP-BCMA
may be renally cleared, which is a result that is inconsistent
with previous literature.46,47
It should be noted that our experimental constructs intro-
duce features of potential clinical novelty that bypass many of
the limitations seen with other diagnostic agents used for the
detection of MM. For instance, unlike with experimental
immunoconjugates that are employed with PET/CT, our con-
structs are not reliant upon ionizing radiation and may enable
longitudinal administration to the same subject. Alternatively,
further incorporation of PET radioisotopes within antibody-
conjugated ultra-small NPs may be pursued to enhance sensi-
tivity as compared to bioconjugates of single chelators or to
PET imaging with 18F-FDG. Such targeted agents could be
expected to enable detection of heterogeneous disease foci
that are routinely missed by bone marrow biopsy, which is
prone to sampling error,48 or by blood biopsy, whose results
may be reflective of the partial disease activity of select
clones.49 In conclusion, our results may aﬀord insights into
the fabrication of other targeted and ultra-small NPs that
could help to detect or treat residual disease, thereby improv-
ing the care and survival of MM patients.
Materials and methods
Cell lines
The human MM cell line MM·1S was purchased from ATCC
(Manassas, VA, USA). LUC+-MM·1SGFP cells were generated via
retroviral transduction, using the pGC-GFP/Luc vector, and were
authenticated by short tandem repeat DNA profiling. MM·1S,
OPM2, and KMS11 were cultured in RPMI media, containing
10% fetal bovine serum, 1% PenStrep, and 1% glutamine.
Synthesis of antibody-conjugated gadolinium-containing
nanoparticles (NPs)
Ultra-small, silica-comprised and Gd-containing nanoparticles
(NPs) were provided by NH Theraguix, Inc. (Villeurbanne,
France). In brief, the constructs are synthesized by a top-down
process and are comprised of a polysiloxane shell surrounded
by DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-
4,7,10-triacetic acid), which is covalently-bound to the in-
organic matrix and which further chelates Gd.17,50–52 NP-anti-
body complexes were generated via conjugation of NPs with
mouse anti-human SLAMF7 or anti-human BCMA monoclonal
antibodies (Biolegend Inc., San Diego, CA), using a previously-
reported homobifunctional linker chemistry.53 Briefly, NPs were
diluted in UltraPure water to a final concentration of 50 nM. A
1 : 10 molar ratio of the bissulfosuccinimidyl suberate linker
was then added and mixed with NP suspensions for 30 min at
room temperature to promote the generation of linker-bound
NPs. These surface-modified constructs were then incubated
with the monoclonal antibodies at a 100 : 1 molar ratio; and,
the suspensions were stirred for an additional 1 h at room
temperature. The NP-antibody complexes were purified by cen-
trifugation filtration, using a filtration device equipped with a
50 kDa molecular weight cutoﬀ membrane (Milipore) that was
spun at 15 000 rcf, and were subsequently resuspended in PBS
(1 M). This process was conducted in triplicate to assure
removal of all excess free nanoparticles into the filtrate and to
concentrate the suspensions of pure NP-SLAMF7 and
NP-BCMA. The final concentrations of the NP-antibody com-
plexes were determined by ICP-MS, using an Agilent 7900
instrument (Agilent Technologies, Inc., Santa Clara, CA).
In vitro assays determining the specificity of NP-antibody
complexes to bind MM cells
Flow cytometry analyses of diﬀerent MM cell lines treated with
various NP-antibody complexes were performed by employing
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a competitive binding assay.32 The cells (1 × 106 mL−1) were
incubated with one of three diﬀerent pool sets (for 1 h at
37 °C), consisting of free anti-IgG antibodies, anti-BCMA anti-
bodies, or NPs (i.e., unmodified NPs or NP-BCMA; 0.5 mM),
which were each combined with free PerCP/Cy5.5-labeled anti-
human BCMA antibodies. The initial concentration of PerCP/
Cy5.5-labeled anti-human BCMA antibody was 2.5 µg mL−1 (in
the pool set consisting of a 1 : 1 molar ratio) and increased up
to 25.5 µg mL−1 (in the pool set at a 1 : 10 molar ratio). A
decrease in the PerCP/Cy5.5 signal corresponded to compe-
tition with the particular pooled agent for the same surface
antigen on the cells; free anti-BCMA antibodies were used as a
positive control (for competition with PerCP/Cy5.5-labeled
anti-human BCMA antibodies) while free anti-IgG and unmo-
dified NPs constituted the negative controls in the experiment.
To cross-validate the results, ICP-MS was utilized to quantify
the amounts of Gd bound per cell. To perform these later
experiments, the treated MM cells were lysed with 0.3% Triton-
X 100 solution prior to enumeration of the amounts of Gd in
each sample, using ICP-MS.
Animals
All animal procedures were performed in accordance with the
Guidelines for Care and Use of Laboratory Animals as set forth
by the Institutional Care and Use Committee (IACUC) of the
Dana-Farber Cancer Institute (protocol 14-001). LUC+-
MM·1SGFP cells were administered to SCID/beige mice (5 × 10
6
cells per mouse; n = 5 mice per group) via IV dissemination,
establishing an orthotopic xenograft model of human MM.
Tumor growth was monitored weekly by BLI, using an IVIS
Spectrum-bioluminescence and fluorescence imaging system
(Perkins Elmer). Tumor debulking was established by treating
the mice with bortezomib (0.5 mg kg−1 daily ×3 doses) fol-
lowed by melphalan (5.5 mg kg−1 ×1 dose). Preliminary toxicity
studies were conducted in balb/c mice (n = 8 mice per group)
after a single-dose IV administration of NP-BCMA (vide infra).
Dosing with NP-BCMA
ICP-MS was used to confirm the presence of 4 NPs (each with
10 Gd atoms)36 per anti-BCMA antibody in a NP-antibody
complex. Upon injection of 200 µL of a suspension of NP-anti-
body complexes, the dose equivalents were 0.0956 mg (4.8 mg
kg−1) of antibody and ∼550 µg (∼175 µmol kg−1) of Gd per
mouse (ESI Fig. 4†).
In vivo and ex vivo imaging studies
MR image acquisition was conducted with a preclinical Bruker
BioSpec 7T/30 cm USR horizontal bore Superconducting
Magnet System (Bruker Corp., Billerica, MA). A 40 mm volume
radiofrequency (RF) coil was used for both RF excitation and
receiving. Animals were anesthetized with 1.5% isoflurane
mixed in medical air at a flow rate of 2 L min−1. Body tempera-
ture was maintained at 37 °C, using a warm air fan. Animal
respiration and temperature were monitored and regulated by
the SAII monitoring and gating system model 1025T (Sa
Instruments Inc., Stony Brook, NY). Neither cardiac nor respir-
ation gating was applied. Bruker Paravision 6.0.1 was used for
MRI data acquisition. A T1 GRE sequence, employing a rep-
etition time (TR) of 87 ms, an echo time (TE) of 3.9 ms, and a
flip angle of 60°, was utilized for imaging. Acquisition matrix =
256 × 192 pixels; reconstructed matrix = 256 × 256 pixels; slice
thickness = 0.5 mm; FOV = 40 × 24 mm (spine) or 20 × 24 mm
(femur); number of averages = 13; and, scanning time =
∼5 min for each image. When comparing imaging parameters
obtained with the diﬀerent Gd-containing contrast agents,
MRI was performed at various time intervals after contrast
administration; and, the results were compared to baseline
images. For the early diagnostic and post-treatment quantifi-
cation studies, MRI was performed 30 min after IV contrast
injection.
CT acquisitions were conducted on a preclinical Inveon CT
scanner (Siemens) equipped with a 50 kVp source; the image
resolution was 10.2 pixels per mm; and, a slice thickness of
0.1 mm was utilized. CT imaging was performed at various
time intervals and before the injection of each MR contrast
agent in order to compare changes in the SNR for diﬀerent
disease burdens detected via each imaging modality
(vide infra).
As a method of validating the binding of NP-antibody com-
plexes to MM cells, confocal microscopy was performed to
visualize the co-localization of NP-antibody complexes, which
had been labeled with a separate fluorophore, on the surfaces
of LUC+-MM·1SGFP cells. For these experiments, NPs were first
conjugated with Cy5.5–NHS at 1 : 1000 molar ratio of fluoro-
phore to NP, using EDC/NHS chemistry, purified (to remove
unbound fluorophore), and subsequently injected into mice.
MRI commenced at 30 min after administration of various NP-
antibody constructs (i.e., NP, NP-IgG, NP-SLAMF7, or
NP-BCMA); and, the animals were sacrificed immediately
thereafter. Their spines and femurs were excised, flash frozen,
and sectioned; bone marrow was mounted on cover slips
coated with Dapi Fluoromount-G (SouthernBiotech). Confocal
microscopy (Olympus FV12000, Olympus) was then used to
verify co-localization of the two fluorophores on tumor cells.
18F-FDG PET/CT was performed on an Inveon
Multimodality Systems (Siemens Medical Solutions USA Inc.).
Low-dose CT scans were first acquired (80 kVp, 0.5 mA, 220
degree rotation, 600 ms per degree exposure time, 80 μm
reconstruction pixel size) for anatomical reference and to
provide guidance for the delineation of the selected tissue
region/volume of interest (ROI/VOI). Following a bolus IV
injection of approximately 6.5 MBq of 18F-FDG, static PET
emission scans were acquired in list-mode format over 10 min
(60 min post-radiotracer injection) and corrected for decay and
dead time. The acquired data were then sorted into 0.5 mm
sinogram bins and a time frame of 1 s was employed for image
reconstruction, using ordered subset expectation maximization
in 3 dimensions followed by MAP reconstruction (OSEM3D/
MAP; 256 × 256 × 159 matrix size, 0.43 × 0.43 × 0.80 mm3
pixel size, 4 OSEM3D iterations, 18 MAP iterations, b = 0.1
optimized for uniform resolution, FWHM 1.29 mm). PET data
analysis was performed with Siemens Inveon Research
Nanoscale Communication
This journal is © The Royal Society of Chemistry 2019 Nanoscale
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
6 
O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
28
/2
01
9 
11
:0
8:
58
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Workplace software. The radioactivity concentrations within
selected tissues were obtained from mean voxel intensity
values within the VOI and then converted to megabecquerels
per milliliter, using the calibration factor determined for the
Inveon PET system. These values were then divided by the
administered activity in megabecquerels and animal body
weight to obtain an image VOI-derived standardized uptake
value (SUV).
Quantitative comparisons of imaging modalities
Evaluation of the relative detection sensitivity for plasma cells
at diﬀerent time points and/or via diﬀerent imaging modal-
ities was performed by conducting a signal-noise-ratio (SNR)
calculation on each acquired image. These SNR values were
obtained after first performing a 3D segmentation of the spine
and a femur of each animal, using Fiji freeware (https://fiji.sc/).
Each image was normalized to the same intensity level and a
region of interest (ROI), including the whole examined organ
(i.e., spine or femur), was segmented; the signal intensity in
the ROI was recorded and compared to the background level,
which was measured on each scan. SNR and normalized SNR
values were calculated, according to eqn (1) and (2):
SNR ¼ intensity=noise; ð1Þ
Normalized SNRðiÞ ¼ SNRðiÞ=SNRbaseline: ð2Þ
Absolute quantification of the uptake of various Gd-based
contrast agents was determined, using ICP-MS (Agilent 7900)
and by following previously described protocols.17,50,52 Briefly,
animals were sacrificed at 30 min after contrast injection; their
excised organs were dissolved in a 70% HCl solution; and,
the Gd content of each organ was determined by ICP-MS
measurement.
Lambda light-chain quantification
Mice were bled once per week and immediately before
imaging. Serum was separated from blood samples and frozen
at −80 °C until the end of the study. These samples were then
diluted 1 : 10 v : v with PBS and a clinical-grade immunoturbi-
dimetric assay, which is routinely performed in the clinical
laboratories of the Brigham and Women’s Hospital (Boston,
MA), was used to quantify the amounts of lambda light chains
in each sample.
Receiver operator characteristic (ROC) curve
The ROC curve was used to represent the ability of the SNR to
discriminate the presence or absence of tumor cells. The SNR
at 5 weeks post-tumor cell implantation was enumerated for
each of the various imaging modalities and served as a metric
by which to compare their detection sensitivities. The class
was defined for each time point by using the following
method: baseline measurements prior to tumor cell implan-
tation served as the control (Ct0 = 0) and were compared
against subsequent time points (Ct = 1) with the assumption
that tumor cells were thereafter always present. To ensure that
the prediction was not random, a two-sided Wilcoxon rank-
sum test was used. A p-value below 0.05 indicated that the SNR
value for a given class was significantly diﬀerent than that of
another class. The R code used for the AUC calculation and
the statistical analysis are presented in ESI Fig. 15 and 16.†
Preliminary toxicity evaluation
Female balb/c mice were administered (IV) a single dose
(200 μL) of PBS (n = 8 mice), NP-BCMA (n = 8 mice;
174.49 µmol kg−1 of Gd; 4.8 mg kg−1 of anti-BCMA), anti-
BCMA antibody (n = 5 mice; 4.8 mg kg−1), or unconjugated
NPs (n = 5 mice; 183.97 µmol kg−1 of Gd). The body weights of
the animals were monitored daily, starting on the day of injec-
tion. After 21 days, the mice were sacrificed and blood samples
were collected by submandibular puncture to determine basic
metabolic profiles, complete blood counts, and white blood
cell diﬀerential counts. The major organs of the animals were
also collected and stained with H&E prior to histological ana-
lyses by a board-certified veterinary pathologist (Dr. Roderick
Bronson, D.V.M.).
Statistical analyses
All in vitro statistical analyses were performed with GraphPad
Prism software (V.7.1). The ability to discriminate the presence
of MM cells, using each of the diﬀerent detection modalities,
was determined by using R version 3.3.3.
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